Literature DB >> 14999412

[Massive subretinal hemorrhages. A challenge for vitreous body surgeons].

J C Schmidt1, C H Meyer, S Hörle.   

Abstract

BACKGROUND: In patients with advanced age-related macular degeneration (AMD), massive subretinal hemorrhage may sometimes be the reason for a loss of peripheral vision, leading to a significantly reduced quality of life. PATIENTS AND METHODS: During the years 1995-2001 we operated five eyes (five consecutive patients) with acute massive subretinal hemorrhage extending into all four quadrants and profoundly reduced vision in the fellow eye due to a Junius-Kuhnt macular scar. Within an interval of 1-2 weeks after the bleeding, pars plana vitrectomy with peripheral retinotomy was performed. After the retina was turned upside down and the partially liquified blood was removed, the underlying subfoveal CNV membrane was removed with a vitrectome. Three phakic eyes required additional cataract surgery and IOL implantation. The retina reattached under PFCL and a silicone oil tamponade applied for 3-6 months.
RESULTS: The removal of the subretinal hemorrhage was without complications. The size of the subretinal membrane was between 4 and 6 PD with partially fibrovascular tissue. After the membrane was removed, a large central pigment epithelium defect made a macular rotation impossible. Visual acuity of hand motion improved from preoperatively 0.05 to postoperatively 1/35 to 0.1 after a follow-up of 3-6 months.
CONCLUSION: In patients with such an extremely reduced visual acuity and visual field, subretinal surgery with removal of the subretinal blood may achieve sufficient vision for the patients' orientation.

Entities:  

Mesh:

Year:  2004        PMID: 14999412     DOI: 10.1007/s00347-003-0912-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  29 in total

1.  Pigment epithelium defects after submacular surgery for choroidal neovascularization: first results.

Authors:  S Hörle; H Pöstgens; J Schmidt; P Kroll
Journal:  Ophthalmologica       Date:  2000       Impact factor: 3.250

Review 2.  [Age-related macular degeneration. 1. Epidemiology, pathogenesis and differential diagnosis].

Authors:  D Pauleikhoff; F G Holz
Journal:  Ophthalmologe       Date:  1996-06       Impact factor: 1.059

3.  Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration.

Authors:  E de Juan; R Machemer
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

4.  Early surgical drainage of macular subretinal hemorrhage.

Authors:  T A Hanscom; K R Diddie
Journal:  Arch Ophthalmol       Date:  1987-12

5.  Massive spontaneous choroidal hemorrhage.

Authors:  Sam S Yang; Arthur D Fu; H Richard McDonald; Robert N Johnson; Everett Ai; J Michael Jumper
Journal:  Retina       Date:  2003-04       Impact factor: 4.256

6.  Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration.

Authors:  J F Vander; J L Federman; C Greven; M M Slusher; V P Gabel
Journal:  Ophthalmology       Date:  1991-01       Impact factor: 12.079

7.  Analysis of digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration.

Authors:  Steffen Schmitz-Valckenberg; Jork Jorzik; Kristina Unnebrink; Frank G Holz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-02       Impact factor: 3.117

8.  Relation of the functional and structural fundus changes after submacular surgery for neovascular age-related macular degeneration.

Authors:  H L Hudson; D A Frambach; P F Lopez
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

9.  Surgical extraction of subfoveal choroidal new vessels and submacular haemorrhage in age-related macular degeneration: results of a prospective study.

Authors:  A Scheider; O Gündisch; A Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-01       Impact factor: 3.117

10.  Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants.

Authors:  F el Baba; W H Jarrett; T S Harbin; S L Fine; R G Michels; A P Schachat; W R Green
Journal:  Ophthalmology       Date:  1986-12       Impact factor: 12.079

View more
  7 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  Which treatment is best for which AMD patient?

Authors:  P Kroll; C H Meyer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

3.  [Massive subretinal hemorrhage and anticoagulants. An unfortunate combination?].

Authors:  C Kuhli-Hattenbach; W Miesbach; I Scharrer; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

4.  Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage.

Authors:  Y Oshima; M Ohji; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

5.  [Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration].

Authors:  F Höhn; A Mirshahi; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

6.  The end of submacular surgery for age-related macular degeneration? A meta-analysis.

Authors:  Christiane I Falkner; Harald Leitich; Florian Frommlet; Peter Bauer; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-04       Impact factor: 3.117

Review 7.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.